<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:department>Sch of Geography, Earth &amp; Env Sciences</gtr:department><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/D5820860-9A1D-487E-A8E6-68BFBFAD4CAE"><gtr:id>D5820860-9A1D-487E-A8E6-68BFBFAD4CAE</gtr:id><gtr:firstName>Ian</gtr:firstName><gtr:otherNames>Alston</gtr:otherNames><gtr:surname>Rowe</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0800476"><gtr:id>CF2EEE7C-36ED-451C-9D81-97AD33A2E3EB</gtr:id><gtr:title>A role for hepatic sinusoidal endothelial cell antigen presentation in the generation of immune tolerance in hepatitis C</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0800476</gtr:grantReference><gtr:abstractText>170 million people worldwide are infected with the hepatitis C virus (HCV). A significant proportion of infected individuals develop liver scarring (cirrhosis) and liver cell cancer. To access the liver cells which the virus can infect it enters the liver via blood vessels in the liver called sinusoids. These are lined by specialised cells - hepatic sinusoidal endothelial cells (HSEC) - which express receptors that can bind HCV.

In health these cells play an important role in scavenging food proteins and other molecules from the blood and can interact with cells of the immune system. The effect of this interaction is to prevent the immune system from destroying harmless food proteins by a process called immune tolerance. We hypothesise that HSEC are critical in HCV infection by 1) taking up the virus from blood and concentrating it in the liver and 2) inducing immune tolerance to the virus, preventing its effective clearance from infected liver cells.

We will study HSEC from human tissue to determine how they interact with HCV and the immune system in HCV infection. Increased understanding of this critical aspect of the disease will allow us to develop new therapies to prevent chronic infection with HCV.</gtr:abstractText><gtr:technicalSummary>Hepatitis C virus (HCV) infects an estimated 170 million people worldwide. A significant proportion of infected subjects are at risk of developing serious progressive liver disease. HCV is likely to enter the liver through the sinusoidal blood and come into contact with hepatic sinusoidal endothelial cells (HSEC) before infecting hepatocytes. The host groups have shown that HSEC express receptors known to interact with the virus but do not permit viral entry.

The immune response to HCV infection is often blunted and this results in a failure to clear the virus and chronic liver injury. The role of HSEC in the immune response to HCV infection is poorly understood. HSEC do scavenge macromolecules and can process and present antigen. Antigen presented in this way to na&amp;iuml;ve CD4+ T lymphocytes promotes tolerance rather than immunity. HSEC also express Toll-like receptors (TLR) and are therefore involved in both the innate and adaptive immune response.

We hypothesise that HSEC play a major role in viral persistence by concentrating virus in the sinusoids and by promoting HCV antigen specific tolerance. We will examine this by first defining the immunophenotype of HSEC in vitro and in vivo. Specifically, we will examine HSEC expression of the C-type lectins, scavenger receptors and TLR by immunohistochemistry, qRT-PCR, cell based ELISA, confocal microscopy and flow cytometry. We will also examine the effect of receptor activation on the profile of induced cytokines by multiplex bead array. Subsequently we will determine the effect of HCV and virus encoded proteins on HSEC function, receptor expression and cytokine secretion in vitro. We have previously shown that co-culture of HSEC with hepatocytes reduces HCV infection and we will determine whether HCV antigen exposure modulates HSEC proliferation, adhesion molecule expression and cytokine secretion. Finally we will compare antigen presentation by HSEC and dendritic cells (DCs) isolated from HLA-A2 donors, where wel-defined HCV epitopes exist. Lymphocyte proliferation will be determined by CFSE labelling and the nature of activation by the measurement of secreted and intracellular and secreted cytokines.

We believe that HSEC by promoting HCV antigen specific tolerance play a key role in the development of chronic HCV infection. Improved understanding of factors that promote chronic HCV infection allows the development of rational novel treatments for this important disease.</gtr:technicalSummary><gtr:fund><gtr:end>2012-01-04</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-01-05</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>190664</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Centre for Immune Regulation</gtr:department><gtr:description>MRC Centre for Immune Regulation</gtr:description><gtr:id>262981CA-67F3-41A4-B3C1-51C561ECCB12</gtr:id><gtr:impact>Pending</gtr:impact><gtr:outcomeId>QLZQ5tvSbD5-1</gtr:outcomeId><gtr:partnerContribution>Core facilities</gtr:partnerContribution><gtr:piContribution>Clinical research study</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>World Hepatitis Day Event - Birmingham</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>B39A2EF7-94FF-4964-B4EE-2E0181D54322</gtr:id><gtr:impact>Presentation to patient groups, media and Chair of Cross-party Committee on Liver Disease

Positive feedback regarding importance of basic research in disease mechanisms</gtr:impact><gtr:outcomeId>48922FEEADE</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>204384</gtr:amountPounds><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Roche Organ Transplant Research Foundation</gtr:description><gtr:end>2014-10-02</gtr:end><gtr:fundingOrg>Roche Organ Transplantation Research Foundation (ROTRF)</gtr:fundingOrg><gtr:id>8885DA27-634C-4CFD-9EEF-010A11BB934B</gtr:id><gtr:outcomeId>TKXnmueKFUj0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Removal of recommendation for hepatitis A vaccination from guidelines for management of patients with hepatitis C virus infection</gtr:description><gtr:geographicReach>Asia</gtr:geographicReach><gtr:guidelineTitle>EASL clinical practice guidelines: management of hepatitis C virus infection</gtr:guidelineTitle><gtr:id>17B1E21E-9FC1-4D54-A7B8-6F64114A4641</gtr:id><gtr:outcomeId>545e5fc3b3eda2.04984779</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>This drug was the first host targeting entry inhibitor trialled in hepatitis C infection. The study done in Birmingham was the proof of concept study for applicability in liver transplantation. The study identified an effect of treatment but this was not sufficient for further clinical development.</gtr:description><gtr:id>F76A7BA7-181E-4C2C-8EF0-6641E47391DD</gtr:id><gtr:impact>As an experimental medicine study detailed information regarding the kinetics of hepatitis C virus (HCV) in the plasma were collected together with tissue samples from the explanted liver. These samples have enabled a greater understanding of the genetic evolution of HCV, informing studies of viral resistance to conventional antiviral treatments.</gtr:impact><gtr:outcomeId>58c8f8a3871269.78267237</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Closed</gtr:status><gtr:title>ITX5061 in liver transplant recipients</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2015</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>1D62D826-9D0A-4405-A86D-A1D0103C9B41</gtr:id><gtr:title>A dual role for hypoxia inducible factor-1a in the hepatitis C virus lifecycle and hepatoma migration.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a7463d1f8fa86587b5c95fd20445a75"><gtr:id>1a7463d1f8fa86587b5c95fd20445a75</gtr:id><gtr:otherNames>Wilson GK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>pm_16399_29_22178269</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F75255E3-5FD3-4C2C-80AF-252F7B50D7BE</gtr:id><gtr:title>Protease inhibitors for treatment of genotype 1 hepatitis C virus infection.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68859e2678f8b3f51bdc173b90573c7b"><gtr:id>68859e2678f8b3f51bdc173b90573c7b</gtr:id><gtr:otherNames>Rowe IA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>hs3SYKYyemN</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6B2F8B87-FC17-41E0-A109-EA25D1A4A718</gtr:id><gtr:title>High resolution sequencing of hepatitis C virus reveals limited intra-hepatic compartmentalization in end-stage liver disease.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fc69287aca943f9da74db554607d91d4"><gtr:id>fc69287aca943f9da74db554607d91d4</gtr:id><gtr:otherNames>Hedegaard DL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>58c8f2bfc70891.17412734</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E8DAF8D0-D889-474D-B625-0F2A775DD35B</gtr:id><gtr:title>Retransplantation for graft failure in chronic hepatitis C infection: a good use of a scarce resource?</gtr:title><gtr:parentPublicationTitle>World journal of gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68859e2678f8b3f51bdc173b90573c7b"><gtr:id>68859e2678f8b3f51bdc173b90573c7b</gtr:id><gtr:otherNames>Rowe IA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1007-9327</gtr:issn><gtr:outcomeId>Ve1yT7LKXxv</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AB172C47-A003-405C-AB80-DF2807DED31B</gtr:id><gtr:title>Despite poor interferon response in advanced hepatitis C virus infection, models of protease inhibitor treatment predict maximum treatment benefit.</gtr:title><gtr:parentPublicationTitle>Alimentary pharmacology &amp; therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68859e2678f8b3f51bdc173b90573c7b"><gtr:id>68859e2678f8b3f51bdc173b90573c7b</gtr:id><gtr:otherNames>Rowe IA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0269-2813</gtr:issn><gtr:outcomeId>pm_16399_29_22906241</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>056D0A23-D09B-4462-AC1E-F8654E96F7D3</gtr:id><gtr:title>Response to antiviral therapy in patients with genotype 3 chronic hepatitis C: fibrosis but not race encourages relapse.</gtr:title><gtr:parentPublicationTitle>European journal of gastroenterology &amp; hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/79cafa36227a027998fb99c3364deb9f"><gtr:id>79cafa36227a027998fb99c3364deb9f</gtr:id><gtr:otherNames>Shoeb D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0954-691X</gtr:issn><gtr:outcomeId>E6LDZf3dmTC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0AFA7E23-5AED-4E1B-8535-C5C7F88A1A62</gtr:id><gtr:title>Effect of scavenger receptor class B type I antagonist ITX5061 in patients with hepatitis C virus infection undergoing liver transplantation.</gtr:title><gtr:parentPublicationTitle>Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68859e2678f8b3f51bdc173b90573c7b"><gtr:id>68859e2678f8b3f51bdc173b90573c7b</gtr:id><gtr:otherNames>Rowe IA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1527-6465</gtr:issn><gtr:outcomeId>58c8f23ec68693.01703929</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B26D1F4B-1960-47D6-993B-871B6F771EC1</gtr:id><gtr:title>Assessment of the quality of evidence underlying international guidelines in liver disease.</gtr:title><gtr:parentPublicationTitle>The American journal of gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68859e2678f8b3f51bdc173b90573c7b"><gtr:id>68859e2678f8b3f51bdc173b90573c7b</gtr:id><gtr:otherNames>Rowe IA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0002-9270</gtr:issn><gtr:outcomeId>pm_16399_29_22951868</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BA024973-29E7-464E-BDE0-58F579E12DCE</gtr:id><gtr:title>Hepatitis A virus vaccination in persons with hepatitis C virus infection: consequences of quality measure implementation.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68859e2678f8b3f51bdc173b90573c7b"><gtr:id>68859e2678f8b3f51bdc173b90573c7b</gtr:id><gtr:otherNames>Rowe IA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>pm_16399_29_22371026</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B7182129-9C6A-4644-92E8-5383FFB92A6C</gtr:id><gtr:title>Hepatitis C virus infects the endothelial cells of the blood-brain barrier.</gtr:title><gtr:parentPublicationTitle>Gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e28545930847fbdf21015e10fbfd11d1"><gtr:id>e28545930847fbdf21015e10fbfd11d1</gtr:id><gtr:otherNames>Fletcher NF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0016-5085</gtr:issn><gtr:outcomeId>pm_16399_29_22138189</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>349784F1-04C6-4A37-8A8A-571EE3A5A628</gtr:id><gtr:title>Sorafenib therapy in patients with hepatocellular carcinoma before liver transplantation.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68859e2678f8b3f51bdc173b90573c7b"><gtr:id>68859e2678f8b3f51bdc173b90573c7b</gtr:id><gtr:otherNames>Rowe IA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>QeSbCwVGCUq</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5762357D-4556-4691-8F78-A49754621BEC</gtr:id><gtr:title>Paracrine signals from liver sinusoidal endothelium regulate hepatitis C virus replication.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68859e2678f8b3f51bdc173b90573c7b"><gtr:id>68859e2678f8b3f51bdc173b90573c7b</gtr:id><gtr:otherNames>Rowe IA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>pm_16399_29_23775568</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A488D916-325D-45B1-BF37-88493EACDFC1</gtr:id><gtr:title>Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3d1f365e7f237e849abd7b8a60e266e"><gtr:id>d3d1f365e7f237e849abd7b8a60e266e</gtr:id><gtr:otherNames>Armstrong MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>BQSXixQqxKU</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0800476</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>